Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting
May 02, 2022 16:31 ET
|
Alaunos Therapeutics, Inc.
Preclinical data to be presented highlights the potential ability to generate mbIL-15 TCR-T cells targeting hotspot mutations expressed in solid tumors with enhanced survival capacity HOUSTON, May ...
Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors
May 02, 2022 08:30 ET
|
Alaunos Therapeutics, Inc.
First-in-human non-viral TCR-T cell therapy targeting shared hotspot mutations in solid cancersFirst clinical product manufactured and administered to a patient using the Company’s in house cGMP...
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 30, 2022 07:30 ET
|
Alaunos Therapeutics, Inc.
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and is expected to dose in 2Q 2022Extended CRADA with the National...
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
March 16, 2022 08:30 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended...
Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
March 08, 2022 16:05 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the...
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics
January 26, 2022 07:00 ET
|
ZIOPHARM Oncology Inc
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND...
Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting
November 09, 2021 08:05 ET
|
ZIOPHARM Oncology Inc
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of...
Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
November 08, 2021 16:10 ET
|
ZIOPHARM Oncology Inc
HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021 and...
Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021
November 01, 2021 16:30 ET
|
ZIOPHARM Oncology Inc
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended...
Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway
September 27, 2021 16:05 ET
|
ZIOPHARM Oncology Inc
• Over 50% reduction in personnel • Cost reductions expected to extend the cash runway into the first half of 2023 • The first patient in its TCR-T Library Phase I/II clinical trial is expected to...